- Home
- VOR
as 06-20-2025 4:00pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 22.1M | IPO Year: | 2021 |
| Target Price: | $7.20 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.13 - $1.80 | Next Earning Date: | 08-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Baird Downgrades Vor Biopharma to Neutral From Outperform
MT Newswires
a month ago
Stifel Downgrades Vor Biopharma to Hold From Buy
MT Newswires
a month ago
HC Wainwright Downgrades Vor Biopharma to Neutral From Buy
MT Newswires
a month ago
Wedbush Downgrades Vor Biopharma to Neutral From Outperform, Adjusts Price Target to $0.40 From $7
GlobeNewswire
a month ago
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Simply Wall St.
3 months ago
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
GlobeNewswire
3 months ago
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
GlobeNewswire
4 months ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.